A review of the first year of Medicare coverage of erythropoietin. by Griffiths, RI et al.
UCSF
UC San Francisco Previously Published Works
Title
A review of the first year of Medicare coverage of erythropoietin.
Permalink
https://escholarship.org/uc/item/1gw9d102
Journal
Health care financing review, 15(3)
ISSN
0195-8631
Authors
Griffiths, RI
Powe, NR
Greer, J
et al.
Publication Date
1994
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
A Review of the First Year of Medicare Coverage 
of Erythropoietin 
Robert I. Griffiths, M.S., Sc.D., Neil R. Powe, M.D., M.P.H., M.BA., 
Joel Greer, Ph.D.,Gregory de Lissovoy, Ph.D., Gerard F. Anderson, Ph.D., 
Paul K. Whelton, M.D., M.Sc., Alan J. Watson, M.D., and Paul W. Eggers, Ph.D. 
Recombinant human erythropoietin 
(rHuEPO) is a new drug for treating ane-
mia associated with end stage renal disease 
(ESRD). In a study of rHuEPO diffusion, 
costs, and effectiveness, we analyze ESRD 
program data and all claims submitted to 
Medicare for reimbursement of rHuEPO 
administered to ESRD dialysis patients. 
Access to rHuEPO was rapid and extensive 
during the first year of Medicare coverage. 
Dosing of rHuEPO and achieved hematocrit 
were lower than expected based on the results 
of clinical trials. rHuEPO cost Medicare 
$144 million in its first year. The analysis of 
insurance claims data allowed effective mon-
itoring of access, costs, and effectiveness of 
this new biotechnology. 
BACKGROUND 
Pharmaceutical products developed 
through advances in recombinant biotech-
nology have been reviewed by the Food 
and Drug Administration (FDA) and are 
now in use in routine clinical practice. 
Some of these products, such as mono-
clonal antibodies, interleukins, and colony 
stimulating factors, have received exten-
sive media and clinical attention because of 
their potential to save lives and to improve 
quality of life. Yet many come with a heavy 
price tag and are likely to have a substantial 
financial impact on patients, providers, 
and third-party payers such as Medicare. 
Enthusiasm for these products may be 
tempered because they arrive at a time of 
great concern over the escalating cost of 
health care, a substantial component of 
which has been attributed to widespread 
use of new medical technologies, including 
pharmaceuticals. 
RECOMBINANT HUMAN 
ERYTHROPOIETIN 
rHuEPO was one of the first recombinant 
pharmaceutical products to receive FDA 
approval for use in clinical practice. 
rHuEPO represents an important advance 
for the treatment of anemia (pathological 
deficiency of red blood cells) associated 
with renal disease. Normal kidneys pro-
duce erythropoietin, which acts on blood-
forming organs (bone marrow) to stimulate 
the growth and differentiation of red blood 
cells, the transporters of oxygen to vital 
body tissues. However, in many patients 
with ESRD, production of erythropoietin 
is impaired or non-existent rHuEPO was 
developed to supplement or replace 
production of natural erythropoietin in such 
patients (Watson and Spivak, 1988; Erslev, 
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1991). In clinical trials, rHuEPO raised and 
sustained hematocrit (a measure of red blood 
cell volume) safely and effectively in a dose-
dependent fashion (Eschbach et al., 1987, 
1989; Winnerls et al., 1986; Nissenson, 1991). 
rHuEPO also alleviated symptoms of anemia 
and improved quality of life of ESRD patients 
(Evans et al., 1990; Laupacis, 1990; Canadian 
Erythropoietin Study Group, 1990). 
Medicare, which covers approximately 93 
percent of all ESRD patients, began financial 
coverage for rHuEPO as soon as it received 
FDA approval in July 1989. Coverage at that 
time was $40 per administration of less than 
10,000 units (U) and $70 per administration 
of greater than or equal to 10,000U. In estab-
lishing initial coverage and payment policy, 
Congress and HCFA attempted to balance 
the need for an appropriate rate of return on 
investment for the firms that had developed 
rHuEPO, reasonable payment to providers 
for administration, and the need for cost 
containment in the Medicare program 
(U.S. Congress, Office of Technology 
Assessment, 1990; U.S. Department of 
Health and Human Services, Office of the 
Inspector General, 1990). 
There were a number of payer, provider, 
and patient concerns regarding the clinical 
and financial impacts of prescribing 
rHuEPO to anemic ESRD patients. 
Policymakers 
The Health Care Financing Administration 
(HCFA) was interested in assuring that 
access to appropriate quantities of rHuEPO 
would be based on clinical need. Also, HCFA 
was interested in monitoring the therapeutic 
benefits of rHuEPO in clinical practice in 
order to evaluate the return on what was 
expected to be a considerable investment in 
rHuEPO. Furthermore, HCFA was con-
cerned with the financial implications of 
rHuEPO, with respect to both the costs 
associated with providing rHuEPO and the 
savings associated with any reduction in 
other medical services because of the 
therapeutic benefits of rHuEPO. 
Providers 
Clinicians were concerned with prescrib-
ing rHuEPO based on clinical need while 
minimizing the risk of adverse outcomes. 
Dialysis facilities were concerned that 
rHuEPO prescription patterns provided 
appropriate care without imposing a 
financial burden. 
Patients 
Patients were eager to receive rHuEPO 
with hopes that it would improve their qual-
ity of life and everyday functioning. 
However, they also were concerned with 
the potential economic burden of copayment for rHuEPO, since Medicare pays 
only 80 percent of allowed charges. 
In order to monitor use of rHuEPO and 
to evaluate coverage and payment policy, 
HCFA required ESRD providers to collect 
and report 3 pieces of information on their 
billing claims for rHuEPO reimbursement: 
(1) the final dose of rHuEPO prescribed 
during each period (usually 1 month) of 
billed care; (2) the number of rHuEPO 
administrations during that period; and (3) 
the patient's hematocrit measured at the 
final rHuEPO administration of the period. 
Hematocrit is the ratio of the volume of 
red blood cells to the total volume of blood 
and is usually reported as a percentage. 
Hematocrit in normal females ranges from 
37 to 48 percent and from 42 to 52 percent 
in normal males (Jordan et al., 1992). In 
patients with ESRD who are not treated 
with transfusions or rHuEPO, hematocrits 
are much lower (Leaf and Cotran, 1976), 
typically in the range of 20 to 25 percent. 
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In this study, hematocrit was used as 
a measure of the clinical effectiveness 
of rHuEPO. 
Collection of the information required by 
HCFA began concurrently with Medicare 
coverage of rHuEPO. This information 
became part of the claims history of 
patients and was incorporated into the 
ESRD Program Management and Medical 
Information System (PMMIS), which con-
tains demographic and clinical information 
on Medicare-entitled ESRD patients. 
Recognizing that rHuEPO is a prototype 
for the kinds of issues arising from the use 
of, and coverage and payment for, new 
biotechnology pharmaceuticals, HCFA com-
missioned a study of the clinical and eco-
nomic impact of rHuEPO during the first 
year of Medicare coverage. Data elements in 
the ESRD PMMIS formed the basis for our 
evaluation of Medicare coverage of rHuEPO 
during the first year of its introduction into 
routine clinical practice. In this article, we 
synthesize the key findings of this study. 
Selected and more detailed clinical reports 
are available elsewhere (Powe et al., 1991, 
1992, 1993; de Iissovoy et al., 1991). This 
article focuses broadly on how claims data 
can be used in reviewing coverage and pay-
ment policy for drug therapy. We describe 
the patients who received rHuEPO during 
the first year of Medicare coverage, examine 
barriers to access, describe rHuEPO dosing 
patterns and effectiveness in routine clinical 
practice, and compute the cost of rHuEPO to 
the Medicare program. We also discuss the 
potential financial incentives created by 
Medicare coverage policy and their role in 
shaping provider behavior. Finally, we con-
sider options in setting and revising optimal 
payment policy and make suggestions for 
monitoring the early use of new technolo-
gies that have substantial clinical and eco-
nomic impacts on the Medicare program 
and its beneficiaries. 
PRINCIPAL FINDINGS 
Access 
Ensuring access to life-saving dialysis 
care was a primary concern of patients, 
clinicians, and Congress in 1972, when 
Medicare coverage was extended to 
patients with ESRD who are either directly 
eligible or dependent upon someone who is 
eligible for Social Security (Rettig and 
Levinsky, 1991). Twenty years later, ensur-
ing access was again a concern, but this 
time to rHuEPO. 
We investigated access to rHuEPO by 
dialysis-dependent ESRD patients during 
the first year of Medicare coverage to 
determine the extent and rate of increase 
of use of rHuEPO by providers and to iden-
tify patient characteristics associated with 
receiving rHuEPO. The design of the 
investigation included longitudinal and 
cross-sectional analyses of claims data 
using descriptive and confirmatory analyti-
cal techniques, such as logistic regression, 
to identify factors associated with receiving 
rHuEPO. We hypothesized that females 
might be more likely to receive rHuEPO 
than males because the prevalence of ane-
mia in ESRD may be greater among 
females than among males. We also 
hypothesized that black patients might be 
less likely to receive rHuEPO because a 
variety of studies have demonstrated that 
black people often receive less access to 
high-cost medical care. 
During the first year of Medicare cover-
age the diffusion of rHuEPO was rapid. In 
July 1989, the first month that rHuEPO 
was covered by the Medicare program, 
3.9 percent (3,658 out of a total 92,113 
ESRD beneficiaries) of patients enrolled in 
the ESRD program, who had a claim for 
dialysis paid by Medicare, and had never 
received a transplant, received rHuEPO. 
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This increased to 53 percent (53,394 out of a 
total 100,749 ESRD beneficiaries) 11 
months later. Access to rHuEPO varied 
markedly according to dialysis modality 
(hemodialysis versus peritoneal dialysis) 
and by site of service (in-center versus 
home) (Powe et al., 1992). Figure 1 illus-
trates the difference in monthly rHuEPO 
use between patients undergoing hemodial-
ysis or peritoneal dialysis in Medicare-
certified facilities, compared with their 
counterparts who were treated with home 
hemodialysis or home peritoneal dialysis. 
Diffusion of rHuEPO into the in-center 
hemodialysis population began rapidly fol-
lowing HCFA coverage and FDA approval. 
However, the rate of increase in diffusion 
declined gradually toward the end of the 
first year. Several factors may have been 
responsible for this pattern of diffusion. 
First, Medicare elected to begin coverage 
for rHuEPO administered in a dialysis cen-
ter (or physician's office) immediately fol-
lowing FDA approval. Medicare's decision 
to provide such coverage removed the 
largest financial barrier to access for in-
center hemodialysis patients. Second, posi-
tive results from rHuEPO clinical trials in 
this population were presented at national 
meetings of nephrologists and appeared in 
the medical literature (Eschbach et al., 
1987; Winnerls et al., 1986) months prior to 
rHuEPO's approval by the FDA rHuEPO 
also had received a great deal of advertis-
ing and media attention prior to approval, 
suggesting that providers and patients 
were probably aware of its potential bene-
fits in clinical practice. The ability to dis-
seminate material to readily identifiable 
dialysis centers may have enhanced the 
effectiveness of advertising. 
In contrast to the in-center hemodialysis 
population, diffusion into the home dialysis 
and in-center peritoneal populations was 
slower, and rHuEPO did not achieve a similar 
level of use by the end of the first 12 months 
of HCFA coverage. In most months, the pro-
portion of in-center hemodialysis patients 
who received rHuEPO was more than double 
the proportion of in-center peritoneal, home 
hemodialysis, or home peritoneal dialysis 
patients. Almost 60 percent of in-center 
hemodialysis patients were receiving 
rHuEPO by June 1990 compared with less 
than 30 percent of those being treated with 
any of the other major dialysis modalities. We 
considered the possibility that demographic 
or clinical differences between patients receiv-
ing different types of dialysis at different sites 
might have been responsible for these 
observed differences. However, multiple logis-
tic regression analysis, adjusting for patient 
clinical and demographic characteristics, 
showed similar patterns (Powe et al., 1992). 
One explanation for the observed differ-
ence between access to rHuEPO in home 
and in-center dialysis patients is that, 
until July 1, 1991, Medicare did not pay 
for rHuEPO that was self-administered 
(U.S. Congress, Office of Technology 
Assessment, 1990). Unlike other types of 
home health services, receiving dialysis at 
home does not entail regular visits to the 
home by health care providers who could 
administer rHuEPO. Therefore, during this 
period, home dialysis patients faced a trade-
off between fewer visits, a convenience of 
home dialysis, versus visiting a treatment 
facility more often to receive rHuEPO and 
having Medicare pay for rHuEPO. 
Peritoneal dialysis usually entails greater 
participation by the patient (e.g., in the 
processes of initiating and monitoring the 
process of dialysis, and of exchanging the 
dialysate), in contrast to in-center hemodial-
ysis where dialysis is performed by health 
care professionals. Therefore, patients 
receiving peritoneal dialysis may be healthi-
er than those receiving hemodialysis 
in-center and have less need for rHuEPO. 
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A smaller proportion of males than 
females received rHuEPO in each month 
during the study period (Figure 2). 
Because females in the general population 
have lower hematocrits than males (Jordan 
et al., 1992), the prevalence of anemia in 
ESRD patients may be higher in females 
than in males. (There are no definitive 
studies, to the best of our knowledge, how-
ever, that confirm or refute this opinion.) 
Overall, in unadjusted analysis, a slightly 
smaller proportion of black patients than 
white patients received rHuEPO in each 
month of the study period (Figure 3). This 
difference became progressively smaller 
during later months and had virtually 
disappeared by the end of the study period. 
However, once the data were compared 
adjusting for dialysis modality, the 
differences between treatment rates in 
black patients and white patients became 
more pronounced. The proportion of black 
patients on in-center hemodialysis who 
received rHuEPO was approximately 8 per-
cent lower, on average, than the corre-
sponding proportion of white patients on 
Figure 2 
Percent of ESRD Patients Receiving Recombinant Human Erythropoietin (rHuEPO), by Gender: 
July 1989 – July 1990 
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NOTE: ESRD is end stage renal disease. 
SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: Data from the Medicare ESRD 
Program Management and Medical Information System, 1990. 
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Figure 3 
Percent of ESRD Patients Receiving Recombinant Human Erythropoietin (rHuEPO), by Race: 
July 1989 – July 1990 
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NOTE: ESRD is end stage renal disease. 
SOURCE: Health Care Financing Administration, Bureau of Data Management and Strategy: Data from the Medicare ESRD 
Program Management and Medical Information System, 1990. 
Black Patients 
White Patients 
in-center hemodialysis who received 
rHuEPO; the proportion of black patients on 
home peritoneal dialysis was, on average, 3 
percent lower. Multivariate logistic regres-
sion analysis of rHuEPO use in June 1990 
suggested that black patients were signifi-
cantly less likely (odds ratio 0.88; 95-percent 
confidence interval 0.86 - 0.91) than white 
patients to receive rHuEPO treatment 
(Powe et al., 1992) 
Of considerable concern in monitoring 
payment policy is the possibility that non-
clinical factors affected prescribing of 
rHuEPO. Although the black and white 
discrepancy in access to rHuEPO identified 
in multivariate analysis could be due to a 
lower prevalence of anemia among black 
people, it may be the case that black people 
find medical care less accessible. Therefore, 
there is cause for concern that the differ-
ences in access to rHuEPO between black 
patients and white patients that we observed 
may not reflect actual need for the drug. 
Perhaps fewer black patients receive 
rHuEPO because black people are less like-
ly to obtain coinsurance to cover the 20 per-
cent patient copayment associated with all 
Medicare Part B services. The burden of 
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the Part B copayment associated with 
receiving rHuEPO is likely to be consider-
able. For instance, during the first year of 
coverage by Medicare the patient was 
responsible for $8 (20 percent of $40) of the 
cost of each administration. If the patient 
were to receive 3 administrations of 
rHuEPO per week the cost of rHuEPO to 
the patient or to his or her coinsurance 
would be $24 per week or $1,248 per year. 
The rate and extent of rHuEPO diffusion 
also varied according to patient age. 
Although patients 65 years of age or over 
were among those least likely to receive 
rHuEPO in July 1989, they were the most 
likely to receive rHuEPO in June 1990. 
There were marked differences in treat-
ment rates of rHuEPO according to the 
underlying cause of renal failure. Figure 4 
shows the rate and extent of diffusion in 
patients with 4 causes of ESRD: (1) multi-
ple myeloma, (2) polycystic kidney disease, 
and the 2 most common causes of kidney 
failure, (3) diabetes mellitus, and (4) hyper-
tension. Figure 5 illustrates the rate and 
extent of rHuEPO diffusion in 4 networks 
that were representative of the diverse pat-
terns of diffusion by ESRD region (States 
were grouped by ESRD network). The 
regional differences in rHuEPO treatment 
patterns were also observed in multivariate 
logistic regression which adjusted for 
other patient clinical and demographic 
characteristics. Although we do not fully 
understand the causes of these substantial 
geographic differences, and it is unlikely 
that the ESRD networks had a direct 
impact on rHuEPO treatment decisions, 
differences in the characteristics of 
patients in different networks may have 
been large enough to produce variability in 
rHuEPO treatment rates. One possible 
explanation is that patient ability to meet 
Medicare copayment for rHuEPO is both a 
determinant of access to rHuEPO and a 
factor that varies by region or State. 
Medicare reimbursement alone may be 
insufficient to cover the provider's cost of 
administering rHuEPO. The provider's 
decision to administer rHuEPO or the 
patient's decision to receive rHuEPO may 
be based, in part, on the patient's ability to 
pay the copayment. This may vary by State 
because of variability in State government 
programs that may finance care for 
indigent ESRD patients. 
rHuEPO diffusion into the ESRD popula-
tion during the first year of Medicare cov-
erage appears to have occurred rapidly. 
Although our data do not permit determi-
nation of the relative role that clinical and 
non-clinical factors played in diffusion, the 
results suggest that both shaped diffusion 
of rHuEPO during the first year of 
Medicare coverage. For instance, patients 
with polycystic kidney disease as an under-
lying cause of renal failure received 
rHuEPO least often. This is consistent with 
clinical expectations because polycystic 
kidneys often continue to produce natural 
erythropoietin. Further diffusion of 
rHuEPO is likely to depend on a number of 
factors: the continued willingness of physi-
cians to substitute rHuEPO for other thera-
pies, such as transfusions or androgens, 
which are already effective in alleviating 
anemia but have significant side effects; 
the ability to overcome socioeconomic bar-
riers to access; and the actual prevalence of 
anemia in the incident ESRD population. 
Dosing 
The intensity of drug therapy can influ-
ence both effectiveness and costs, out-
comes of extreme interest to policymakers. 
It can also influence providers' financial sta-
tus depending on the structure of payment 
policy. As a result of experience with 
rHuEPO in clinical trials (Eschbach et al., 
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1987, 1989; Winnerls et al., 1986), initial 
dosing of 50 to 150U per kilogram of body 
weight intravenously 3 times per week was 
approved by the FDA. The National Kidney 
Foundation (1989) also recommended 
150U per kilogram of body weight. 
Assuming that the average ESRD patient 
weighs between 60 kg and 80 kg, one 
would have expected to observe an aver-
age initial dose of between 3,000 and 12,000 
U per administration. In addition to a range 
of expected average dose, experience from 
clinical trials suggested two distinct phases 
of dosing were likely: an initial phase of rel-
atively large rHuEPO doses lasting approx-
imately 3 months and designed to raise 
hematocrit above 30 percent; and a mainte-
nance phase of smaller doses, adminis-
tered thereafter on a chronic basis and 
designed to maintain the target hematocrit 
level once it had been attained. 
We performed an analysis of rHuEPO 
dosing practices during the first year of 
Medicare coverage to compare dosing in 
routine clinical practice with dosing in 
clinical trials and dosing recommended at 
the time rHuEPO was approved for mar-
keting. We also sought to identify patient 
characteristics associated with lower or 
higher doses. For example, we hypothe-
sized that females would receive less 
rHuEPO than males because they gener-
ally weigh less. Unadjusted and multiple 
linear regression analyses were per-
formed on cross-sectional and longitudi-
nal claims data to test this hypothesis. 
In contrast to the expected average dose, 
the observed average dose in the first 
month of rHuEPO therapy was 2,752U for 
59,462 patients who began rHuEPO during 
any calendar month from July 1989 to June 
1990. The average dose fell to 2,668U in the 
fourth month of rHuEPO therapy for those 
40,891 patients who received rHuEPO for 
at least 4 months during the study period. 
The mean dose was 3,576U in the first 
month and 3,243U in the fourth month of 
rHuEPO use for 2,619 patients who began 
rHuEPO therapy in July 1989, a reduction 
of 9.3 percent. For patients who began 
rHuEPO later in the study period, the 
mean first month dose was substantially 
smaller, as was the change between first 
and fourth month dose. Mean first and 
fourth month doses were significantly 
lower for females than for males. Figure 6 
shows that although the average first 
month dose was 2,752U per administration, 
the distribution of average first month dose 
was distinctly bimodal, with peaks at 
2,000U and 4,000U and very few doses 
greater than 4,000U. During this period 
rHuEPO was packaged in 2,000 and 4,000U 
vials, and it is possible that the size of the 
rHuEPO dose administered was based on 
the size of available vials in addition to 
being based on patient weight. 
In general, the average dose used in clin-
ical practice was significantly lower than 
expected based on the experience in clini-
cal trials, FDA approval, and the recom-
mendations of the National Kidney 
Foundation (1989). For patients beginning 
rHuEPO therapy soon after FDA approval, 
there was a steady decline in dosing levels 
between the first and the fourth month of 
therapy and a constant dose or slightly 
increasing dose thereafter. Patients begin-
ning rHuEPO therapy later in the study 
period experienced smaller declines. 
Neither of these patterns defines two 
distinct phases of dosing as recommended 
on the basis of clinical trials. 
One explanation for this finding is that 
clinicians were concerned with the possi-
ble adverse effects associated with increas-
ing their patient's hematocrit too rapidly, 
such as the occurrence of hypertension. 
This may have resulted in a more conserv-
ative approach to dosing designed either to 
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Figure 6 
Distribution of Recombinant Human Erythropoietin (rHuEPO) Dose in the First and Fourth Months 
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minimize the risk of side-effects or to facil-
itate patient management. Another expla-
nation is that clinicians may have believed 
they were achieving satisfactory results 
with relatively low doses of rHuEPO. 
Evidence suggests that clinicians did 
take patient clinical characteristics into 
account when determining rHuEPO dose. 
For instance, clinical trials and product 
labelling advocated dosing based on 
patient weight. Although we did not have 
access to weight data, we observed that 
females received smaller doses than males, 
which is consistent with the fact that 
females generally weigh less. It is note-
worthy that black patients received the 
same amount of rHuEPO as white patients. 
Therefore, although black patients were 
less likely to receive rHuEPO (as dis-
cussed earlier), those who obtained 
rHuEPO received an amount similar to 
white patients. 
Under the Medicare coverage and reim-
bursement policy during the first year, eco-
nomic incentives existed to minimize the 
rHuEPO dose and to provide rHuEPO to a 
large number of patients in order to maxi-
mize profit or break even. All other things 
being equal, the proportion of patients 
receiving rHuEPO in a provider's caseload 
and the average dose among those being 
treated with rHuEPO might have been 
expected to vary depending on the degree 
to which profits are important to a provider. 
In an analysis of 1,968 ESRD providers, 
for-profit independent facilities provided the 
lowest mean caseload dose (2,465U) com-
pared with for-profit hospitals (2,493U), not-
for-profit independents (2,798U), not-for-
profit hospitals (3,081U), and government 
facilities (3,112U) (de Iissovoy et al., 1991). 
The fact that for-profit facilities provided sig-
nificantly smaller doses than either not-for-
profit or government facilities suggests 
that they may have attempted to maximize 
profit on an individual patient basis. For-
profit independent facilities also provided 
rHuEPO to a larger proportion (47 percent 
[n = 862]) of their caseload than not-for-profit 
and other for-profit facilities (35 percent 
[n = 118]) in for-profit hospitals, 46.1 percent 
[n = 244] in not-for-profit independents, 40.4 
percent [n = 353] in not-for-profit hospitals, 
and 26.1 percent [n = 51] in government facil-
ities) . This is also consistent with a profit- ori-
ented behavior which includes maximization 
of the number of profitable administrations of 
rHuEPO. The results of multivariate analy-
ses, which adjust for variation in provider 
caseload characteristics, are consistent with 
those of the unadjusted analyses. 
Our findings are consistent with the 
hypothesis that dialysis providers may 
have provided smaller than expected doses 
in order to break even or to make a profit. 
They are also consistent with the hypothe-
sis that providers might respond different-
ly to incentives under Medicare coverage 
and reimbursement policy, depending on 
the importance of profits. However, it is 
important to recognize that our findings do 
not prove that provider behavior was influ-
enced by financial considerations. 
Several caveats should be kept in mind 
when using these results to compare the 
behavior of for-profit and not-for-profit facil-
ities. First, for-profit facilities face a tax lia-
bility, whereas not-for-profits do not. 
Therefore, for-profit facilities may provide 
smaller doses of rHuEPO in order to retain 
the same excess of revenue over expenses 
after taxes as their not-for-profit counter-
parts. Second, the extent to which the abili-
ty to collect the 20 percent copayment owed 
by patients varies by facility profit status is 
unknown. If patients in for-profit facilities 
have greater ability to meet the copayment 
obligations from their personal resources, 
the actual difference in excess of revenues 
over expenses between for-profit and 
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not-for-profit facilities may be greater than 
that implied by the observed discrepancy 
in dosing. Finally, these results do not nec-
essarily indicate that rHuEPO treatment in 
not-for-profit or government facilities was 
more appropriate than in for-profits. It is 
possible that the lower doses observed in 
for-profit facilities are indicative of greater 
efficiency. Higher doses were not consis-
tently associated with either a more rapid 
increase or higher sustained hematocrit 
than lower doses. 
Effectiveness 
Clinical effectiveness is an important 
outcome for providers, patients, and 
policymakers. We performed an analysis 
designed to determine the effectiveness of 
rHuEPO in routine clinical practice as mea-
sured by the effect on patient hematocrit 
and to identify patient characteristics asso-
ciated with variation in response to 
rHuEPO. Several clinical measures avail-
able on claims data were used to assess the 
effectiveness of rHuEPO treatment. These 
included the proximate indicators hemat-
ocrit and transfusion status. Unadjusted and 
multivariate linear regression were per-
formed to establish the dose-response rela-
tionship in routine clinical practice and to 
identify factors associated with response. 
In general, patient hematocrit increased 
steadily during the first 3 months of thera-
py and then stabilized. Mean hematocrit 
rose from 26.7 percent during the first 
month of rHuEPO treatment to a peak of 
28.9 during the fourth month. Twenty-four 
percent of patients had a hematocrit 
greater than or equal to 30 percent in the 
first month of rHuEPO use compared with 
44 percent in the fourth month. Among 
those patients who received rHuEPO for at 
least 6 months during the study period and 
were enrolled in the ESRD program for at 
least 6 months prior to initiation of 
rHuEPO therapy, 27.1 percent were trans-
fused in dialysis centers during the 
6-month period prior to initiation of 
rHuEPO therapy, whereas only 14 percent 
were transfused in the first 6 months 
following initiation of therapy. 
Manufacturer recommendations includ-
ed a target hematocrit level of 30 percent. 
In general, patient hematocrit stabilized at 
a level lower than expected based on the 
results of clinical trials, which may be due, 
in part, to physicians' belief that there are 
diminishing benefits with regard to the 
oxygen carrying capacity of blood of 
increasing hematocrit beyond this level. In 
contrast to clinical trials where rHuEPO 
obviated the need for blood transfusions, 
blood transfusions in routine clinical 
practice were markedly decreased but not 
totally eliminated. 
In unadjusted analysis, we found that those 
patients receiving rHuEPO experienced, on 
average, a rise in percentage of hematocrit of 
2.47 points. In multivariate analysis, we found 
that the change in percentage of hematocrit 
from the first to fourth month of rHuEPO use 
was significantly related to the logarithm of 
average dose from the first to fourth months 
of rHuEPO use, but that the magnitude of 
this association was small. Therefore, this 
observed dose-response relationship was 
weaker than expected, on the basis of 
clinical trials conducted prior to FDA 
approval of rHuEPO that reported strong 
dose-response relationships. 
Survival 
We examined the trend in survival rates 
for the ESRD population from 1985 to 1990 
to determine whether rHuEPO appeared to 
have an effect on overall survival. Patients 
were considered to have survived a year if 
they were alive and enrolled in the ESRD 
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program on July 1 of one year and did not 
die before June 30 of the following year. We 
used the technique of direct standardiza-
tion (Lillienfeld and Lillienfeld, 1980) to 
adjust for increases over time in the pro-
portion of elderly patients and the propor-
tion of patients with diabetes as an under-
lying cause of renal failure. Both character-
istics are associated with a lower probabili-
ty of survival. The adjusted survival rate 
remained constant across all years at 
approximately 80 percent, suggesting that 
rHuEPO did not affect overall survival 
(Powe et al., 1991). 
Two caveats should be considered. First, 
it is possible that we failed to control for 
other changes in the composition of the 
ESRD population that influence survival. 
Second, the followup period may have been 
too short to observe an effect of rHuEPO. 
Costs 
The cost of pharmaceuticals is an 
increasingly sensitive issue to both policy-
makers and patients, and was identified as 
a major target in the President's health 
care reform proposal. The average 
Medicare expenditures for rHuEPO per 
recipient per month increased from $242 in 
July 1989 to $340 in June 1990. This may be 
due to the fact that in the early months fol-
lowing FDA approval, more patients had 
less than a full month of rHuEPO therapy 
because they were just starting therapy, 
compared with later months, when 
rHuEPO therapy for most patients was 
established and such patients were receiv-
ing rHuEPO for the whole month. 
Likewise, the average copayment cost 
increased from $61 in June 1989 to $85 in 
June 1990. The average copayment cost in 
June 1990 is more representative of future 
copayment costs, and it is likely that yearly 
copayment costs will be at least $1,020. 
However, this estimate ignores the effects 
of payment changes, to $11 per 1,000U of 
rHuEPO administered in January 1991, 
and to $10 per 1,000U in January 1994. 
As might be expected, overall expendi-
tures by Medicare (Medicare-allowed 
charge less 20 percent beneficiary copay-
ment) on rHuEPO increased rapidly during 
the first year of coverage because of imme-
diate and extensive rHuEPO use (Figure 
7). Total expenditures increased from 
$923,000 in July 1989 to $19,200,000 in 
June 1990. Cumulative expenditures by 
Medicare during the first year of coverage 
were $144 million, while cumulative coin-
surance costs were $36 million. Again 
ignoring the possible effects of the 
changes in payment policy, and assuming 
no additional diffusion, cumulative expend-
itures by Medicare would be expected to 
reach $230 million in the second year fol-
lowing FDA approval, which represents an 
increase of approximately 5 percent over 
total Medicare ESRD expenditures in 1988. 
It is also worth noting that the incident 
ESRD population, which continues to grow, 
contains an increasingly large proportion 
of elderly patients who are more likely to 
receive rHuEPO. This suggests that even if 
all clinical need for rHuEPO is currently 
satisfied, expenditures and utilization will 
continue to grow as new patients enter the 
ESRD program. 
It is important to recognize that the 
Medicare expenditures that we measured 
are due only to rHuEPO itself, and therefore 
may not reflect the net impact on Medicare 
expenditures of rHuEPO. The extent to 
which expenditures for rHuEPO are offset 
by savings resulting from the therapeutic 
benefits of rHuEPO, or are increased 
because of side effects of therapy, have been 
projected with decision modeling (Powe, 
Griffiths, and Bass, 1993). The projected 
annual cost of rHuEPO for 53,394 patients in 
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Figure 7 
Monthly Medicare Expenditures for Recombinant Human Erythropoietin: July 1989–June 1990 
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June 1990, adjusted for savings resulting 
from therapeutic benefits and costs result-
ing from side effects, is $227,084,682, 
compared with the unadjusted cost of 
$230,000,000. Information from claims data 
might be used to provide current estimates 
for modeling the extent of additional costs 
or savings resulting from rHuEPO. 
CONCLUSIONS 
Several conclusions may be drawn from 
our study of early rHuEPO use in the 
Medicare ESRD program. Some of these 
may be generalizable to the assessment of 
new biotechnology therapy or other new 
technologies for which Medicare and other 
insurers must make coverage and reim-
bursement decisions. 
Value of Early Monitoring 
First, contrary to a previous appraisal of 
HCFA policy in establishing mechanisms 
to routinely monitor rHuEPO dose and 
patient response (Sisk, Gianfrancesco, and 
Coster, 1991), we found that the decision to 
monitor early utilization of rHuEPO provid-
ed a valuable base of experience for HCFA 
and Congress in their evaluation of pay-
ment policy (Herdman and Sisk, 1990). 
Observation of changes in rHuEPO utiliza-
tion over time, projection of costs and eval-
uation of effectiveness became possible, 
and shed light on how various factors influ-
ence the way new technologies may be 
used in clinical practice. 
As shown, rHuEPO made a dramatic 
entry into ESRD patient care after its 
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approval by the FDA, in large part fueled 
by uniform health insurance coverage for 
patients with ESRD. The rate and extent of 
diffusion, and the effectiveness of 
rHuEPO, have been shaped by a variety of 
factors. Patients appear to have obtained 
access to rHuEPO based on clinical need, 
but economic incentives created by 
Medicare payment policy may also have 
influenced facilities' decisions with respect 
to rHuEPO use and dosing. Furthermore, 
although rHuEPO was effective in increas-
ing hematocrit, the hematocrit levels 
achieved during rHuEPO treatment were 
lower than anticipated on the basis of expe-
rience in clinical trials. Factors that 
appeared to be responsible for the out-
comes we observed, while specific to 
rHuEPO, the ESRD patient population, and 
the ESRD provider community, provide 
valuable insights regarding the relative 
importance of factors that may influence 
how technology is used in clinical practice 
during the early period of its adoption. 
Usefulness of Data Reporting 
Requirements 
Second, data collection was designed not 
only to facilitate evaluation of utilization of 
services but also to provide a specific 
mechanism for monitoring effectiveness 
and quality of care. HCFA included in its 
data collection measures of the intensity of 
rHuEPO utilization (dose and number of 
administrations) and a proxy for health 
status (hematocrit). The incorporation of 
these measures facilitated a rapid, unobtru-
sive and relatively inexpensive means for 
evaluation of the effectiveness of rHuEPO 
therapy throughout all dialysis facilities in 
the United States. Typically, such evalua-
tions through primary data collection 
efforts require a commitment of substan-
tial resources and often provide selected 
and possibly unrepresentative samples of 
patients. In the late 1970s, however, HCFA 
made a substantial investment in creating, 
through collaboration between the Office 
of Research and Demonstrations, the 
Bureau of Data Management and Strategy, 
and the Health Standards Quality Bureau, 
the ESRD PMMIS. The adaptation of the 
PMMIS permitted an evaluation of the 
impact of rHuEPO to take place in a cost-
efficient manner. 
One limitation of the data was that 
hematocrit was only available for those 
who received rHuEPO. As a result, 
although use was rapid and extensive, we 
cannot confirm that everyone with a clini-
cal need received rHuEPO. Hematocrit 
data for all ESRD patients, irrespective of 
rHuEPO use, might be particularly useful 
in determining the importance of non-clini-
cal factors in shaping access to rHuEPO. A 
second limitation was that information on 
patient weight, an important determinant 
of rHuEPO dose in clinical trials, and on 
iron supplementation, which is important 
to clinical effectiveness of rHuEPO, were 
not available. Therefore, variability in dos-
ing and effectiveness may have been due to 
unobserved variability in patient weight 
and rates of iron supplementation. 
One outcome that we could not obtain 
from claims data was change in quality of 
life associated with rHuEPO therapy. 
Improved quality of life may be the most 
important dimension of rHuEPO's benefits 
to ESRD patients. To collect such data, 
HCFA or the National Institutes of Health 
United States Renal Data System could 
administer health status surveys to sam-
ples of ESRD patients, either by phone or 
in person. Medical record review, to identi-
fy clinical barriers to rHuEPO effective-
ness or appropriateness of prescribing, 
might be coordinated through the ESRD 
networks, because their responsibility 
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includes an assessment of quality assur-
ance. These activities, coupled with analy-
sis of claims data, would provide a more 
comprehensive estimation of effectiveness, 
cost-effectiveness and quality of care. 
Payment Policy Revision 
Third, payment policy changed from $40 
for less than 10,000U of rHuEPO and $70 
for 10,000U or more in July 1989 to $11 per 
1,000U of rHuEPO in January 1991. This 
payment was further reduced to $10 per 
1,000U in January 1994. These revisions 
were possible, in part, because of the avail-
ability of representative data on access, 
cost, practice patterns, and effectiveness 
from this early monitoring system and 
because the U.S. Congress Office of 
Technology Assessment (OTA) (1990) had 
previously identified the merits and draw-
backs of several alternative payment policy 
options. For instance, the OTA had evaluat-
ed the incentives and disincentives to ESRD 
providers associated with reimbursement 
based on the number of rHuEPO U admin-
istered, increasing the dialysis capitation 
payment to allow for the expected cost of 
rHuEPO, and providing two levels of reim-
bursement based on dose (the coverage 
policy selected for use during the first year 
following FDA approval). Therefore, when 
data on rHuEPO use during the first year of 
coverage began to appear, HCFA and 
Congress were in a position to evaluate the 
incentives created by the initial payment 
policy and their impact on access, quality 
and cost, and to make an informed decision 
on whether and in what way policy should 
be revised (Herdman and Sisk, 1990). 
RECOMMENDATIONS 
Based on our experience from this analy-
sis of Medicare insurance claims, we make 
several recommendations that form the 
basis of a paradigm for monitoring emerg-
ing medical technologies of extreme impor-
tance to patients, providers and payers. 
First, we recommend that, prior to the cov-
erage of a technology, payers establish an 
advisory group that includes experts from 
administrative departments of insurers 
(program management, claims processing, 
and data base management), from clinical 
medicine, and from health economics and 
finance. Second, this advisory group 
should define the outcomes (e.g., access, 
effectiveness, and costs) that are important 
to patients, providers and payers and 
should develop specific measures of these 
outcomes. Third, the advisory group 
should identify the data needed to con-
struct these measures. Fourth, the feasibil-
ity (advantages and disadvantages) of 
requiring providers to collect and to report 
various types of data to construct these 
measures should be weighed. Finally, a 
timely decision (prior to insurance cover-
age) about the most optimal strategy for 
monitoring the technology should be 
reached and its implementation should be 
facilitated rapidly. 
SUMMARY 
Accurate and timely data were essential in 
evaluating early use of rHuEPO in ESRD 
patients. Data will play an increasingly 
important role if policymakers expect to 
make informed and prompt decisions on 
how payment policy should be revised to 
promote use of pharmaceuticals in a way 
that results in equitable access, containment 
of costs, and improved patient outcomes. In 
the case of rHuEPO, with a change in pay-
ment policy, which was then implemented 
by Congress based on more precise levels 
of dosing, the economic incentives have 
been altered in a way to promote higher 
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doses than those administered during the 
first year of coverage. Continued observa-
tion is necessary, and now possible, to 
assess not only changes in dosing but 
changes in health status and costs which are 
likely to result from the payment change. 
The findings from this study illustrate the 
value of post-marketing surveillance, an 
important aspect of pharmacoepidemio-
logic research (Strom, 1989). Such research 
recognizes that drug effects measured dur-
ing clinical trials designed to provide infor-
mation for FDA approval can be markedly 
different from those measured in routine 
clinical practice. According to the principles 
of pharmacoepidemiology, a variety of influ-
ences that are excluded from or controlled 
for in the assessment of the efficacy of a 
new drug in a clinical trial are important in 
shaping care in clinical practice, and can 
play a major role in determining whether 
patients obtain clinical benefits at a reason-
able cost Some of these include the extent 
to which the patient population in clinical 
trials differs from the general population 
that can potentially receive the drug, the 
amount of pressure for provider economic 
viability created by coverage policy, and the 
quality of patient care in clinical practices 
throughout the United States. 
The relative importance of clinical and 
non-clinical factors in shaping technology 
use may change over time as the epidemi-
ology of disease in the patient population 
changes (growth in numbers of elderly 
ESRD patients), as the provider communi-
ty changes (growth of for-profit and free-
standing facilities), as technology delivery 
is changed (administration of rHuEPO sub-
cutaneously rather than intravenously) and 
as payment policies at the State (Medicaid 
or State kidney disease-specific programs) 
or Federal level change. As a result, pro-
motion of the optimal use of rHuEPO and 
other expensive drugs should be a 
dynamic process which pays attention to 
the changing environment of health care. 
Therefore, the arrival of promising yet 
expensive new recombinant pharmaceuti-
cal products, such as rHuEPO, makes data 
systems for early and sustained evaluation 
more important than ever before. 
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